Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation technique aims to cut side effects in prostate cancer treatment

NCT ID NCT02918253

Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer will receive this targeted radiation. The main goal is to see if the cancer stays under control, while also checking for improvements in urinary, bowel, and sexual function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-dose rate (HDR) brachytherapy (radiation)
What this could lead to
If successful, this approach could offer a way to treat early-stage prostate cancer with fewer urinary, rectal, and sexual side effects, improving quality of life.
What could go wrong
This is a small feasibility study (60 people) with no phase designation, so results are preliminary. It may not show clear benefits or could still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2016

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * ECOG performance status 0 - 2 * Histological evidence of prostate adenocarcinoma * Low- and favorable intermediate-risk prostate cancer * Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed * No contraindications to MRI * Absent or unifocal intraprostatic disease (\<2 separate/distinct lesions), on multiparametric MRI * Baseline IPSS \<18 * No TURP within the past 6 months, nor large TURP defect * Absence of radiological evidence of regional or distant metastases (optional evaluation, at physician discretion) * No previous pelvic and/or prostate EBRT and/or brachytherapy * No contraindications to general anesthesia, or spinal/epidural anesthesia * Absence of bleeding diathesis and/or anti-coagulative therapy that cannot be temporarily ceased during brachytherapy * No contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or colorectal surgery * Negative past medical history of Ulcerative Colitis, Crohn's Disease, Ataxia Telangiectasia, or SLE (except for patients where clinician determines benefit outweighs the risk of radiation) * Absence of latex allergy * No other medical conditions deemed by the PI to make patient ineligible for prostate HDR brachytherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.